CureVac

CVAC

The minimum condition for the offer has been satisfied, with 184,071,410 shares of CureVac, representing approximately 81.74% of CureVac's issued and outstanding shares, tendered prior to the expiration of the initial offering period The subsequent offering period has commenced and will expire at 12:01 a.m. Eastern Time on Thursday, December 18, 2025   MAINZ, Germany, December 3, 2025 – BioNTech SE (Nasdaq: BNTX, “BioNTech”) announced today that 184,071,410 shares of CureVac N.V.

CureVac N.V. ( CVAC ) Shareholder/Analyst Call November 25, 2025 8:00 AM EST Company Participants Mehdi Shahidi Marco Rau Thaminda Ramanayake - Chief Business Officer & Member of Executive Board Alexander Zehnder - CEO, MD & Member of Management Board Presentation Mehdi Shahidi Welcome, everyone, to this Extraordinary General Meeting of Shareholders of CureVac N.V.

TÜBINGEN, DE AND BOSTON, MA / ACCESS Newswire / November 25, 2025 / CureVac N.V. (Nasdaq:CVAC)(CureVac or the Company), a pioneering multinational biotech company developing a new class of transformative medicines based on messenger RNA (mRNA), today announced the voting results of its Extraordinary General Meeting (EGM).

German Federal Cartel Office clearance obtained for the planned BioNTech - CureVac transaction announced on June 12, 2025, marking an important step toward the expected closing later this year Offer period for BioNTech's public exchange offer for all outstanding CureVac N.V. shares began on October 21, 2025, and is scheduled to expire on December 3, 2025 German litigation with Pfizer/BioNTech related to mRNA-based COVID-19 vaccines has been paused pending completion of BioNTech's public exchange offer Received Clinical Trial Application (CTA) clearance from the European Medicines Agency (EMA) for CVHNLC squamous non-small cell lung cancer (sqNSCLC) CVGBM (glioblastoma) Phase 1 Part B remains on track Strong cash and cash equivalents position of €416.1 million as of September 30, 2025, confirming expected cash runway into 2028 CureVac received final audit report relating to the Advance Purchase Agreement with the European Commission for CureVac's first-generation COVID-19 vaccine candidate TÜBINGEN, GERMANY AND BOSTON, MA / ACCESS Newswire / November 24, 2025 / CureVac N.V.

CureVac is a pioneering biotech company focused on mRNA drugs for oncology and vaccines. In biotech, value derives from research quality, patent strength, and clinical success probability, not current revenues. CVAC boasts over 25 years of research and nearly 1,000 mRNA patents, highlighting its intellectual property strength.

CureVac Announces Financial Results for the Second Quarter and First Half of 2025 and Provides Business Updates Entered into a definitive Purchase Agreement pursuant to which BioNTech intends to acquire all shares of CureVac, uniting two highly complementary German companies to bring transformative mRNA-based treatments to patients globally Entered into agreements to resolve and dismiss all pending patent litigation in the U.S. with Pfizer/BioNTech related to mRNA-based COVID-19 vaccines and to set a framework for resolving related ongoing patent disputes outside the U.S. upon closing of BioNTech's acquisition of CureVac Received Clinical Trial Application (CTA) clearance from the European Medicines Agency (EMA) for CVHNLC, a proprietary off-the-shelf cancer immunotherapy candidate targeting squamous non-small cell lung cancer (sqNSCLC) CVGBM glioblastomadata from Part B of Phase 1 remain on track for H2 2025 Strong cash and cash equivalents position of €392.7 million as of June 30, 2025; expected cash runway into 2028 TÜBINGEN, GERMANY AND BOSTON, MA / ACCESS Newswire / August 15, 2025 / CureVac N.V. (Nasdaq:CVAC), a pioneering multinational biotech company developing a new class of transformative medicines based on messenger RNA (mRNA), today announced financial results for the second quarter and first half of 2025 and provided a business update.

GSK PLC (LSE:GSK, NYSE:GSK) will receive an upfront payment of $370 million from CureVac, following a patent settlement involving BioNTech and Pfizer over messenger ribonucleic acid (mRNA) vaccine technology. The deal will also see GSK collect a 1% royalty on United States sales of Pfizer and BioNTech's influenza, COVID-19, and related combination mRNA vaccines from the start of 2025.

CureVac said on Thursday that the company and GSK have entered an agreement to a resolve patent dispute with Pfizer and BioNTech related to mRNA-based COVID-19 vaccines.

TÜBINGEN, GERMANY AND BOSTON, MA / ACCESS Newswire / June 24, 2025 / CureVac N.V. (NASDAQ:CVAC), a pioneering multinational biotech company developing a new class of transformative medicines based on messenger RNA (mRNA), today announced the voting results of the Company's Annual General Meeting.

CVAC jumps 41% in a month after signing a $1.25B deal to be acquired by BioNTech to accelerate mRNA therapy development.